Pharmaceutical giant Pfizer has reduced its 2026 earnings guidance, predicting lower adjusted earnings per share than this year’s figures. The company maintained its 2025 revenue outlook at $62 billion and reiterated a share price range of $3 to $3.15. Analysts see stronger numbers in the same period, but Pfizer’s cautious approach signals potential concerns for investors.
Source: https://www.wsj.com/business/earnings/pfizer-expects-decline-in-covid-19-drug-demand-to-hurt-2026-earnings-9b92553b